FDA Approves First Pancreatic Cancer Drug Targeting RAS

For decades, researchers knew that blocking a cancer-driving gene called RAS could transform pancreatic cancer treatment, but the science seemed impossible. Last week, the FDA approved daraxonrasib, the first drug to successfully target RAS in pancreatic cancer patients, marking a turning point for a disease that kills more than 50,000 Americans each year.

The drug works like molecular glue, sticking to RAS proteins and blocking the signals that fuel cancer growth. More than 90 percent of pancreatic cancer patients carry mutations in KRAS, a gene in the RAS family that drives their tumors.

In a global study of 500 patients who had already tried chemotherapy, daraxonrasib changed the game. Patients taking the drug lived a median of 13.2 months compared to 6.7 months for those on standard chemotherapy. The drug cut the risk of death by 60 percent.

Dr. Brian Wolpin, who led the clinical trial at Dana-Farber Cancer Institute, called it a landmark advance. "For many years, researchers believed that successfully targeting RAS had the potential to transform treatment, but therapeutically blocking RAS signaling proved extraordinarily challenging," he said.

Pancreatic cancer is especially deadly because it rarely causes symptoms until it has already spread. About 80 percent of the 65,000 people diagnosed each year in the U.S. discover their cancer after it has already invaded other tissues. For patients with metastatic disease, the five-year survival rate sits at just 3 percent.

The new treatment also helped tumors shrink or disappear in one-third of patients with RAS mutations, compared to just 12 percent on chemotherapy. Patients experienced longer periods without their cancer worsening, gaining an extra three to four months on average.

The Ripple Effect

This approval represents more than one new drug. It proves that even the most stubborn cancers can be outsmarted with sustained scientific investment. Researchers are already building on this success, working on combination therapies and treatments for earlier-stage disease.

The achievement also signals hope for other cancers driven by RAS mutations, including lung and colon cancer. What seemed impossible just years ago has become reality for patients who desperately needed options.

Common side effects include rash, mouth inflammation, nausea, and diarrhea, but no unexpected safety concerns emerged during testing. Patients can take the medication as a pill at home rather than receiving infusions at a hospital.

For families facing a pancreatic cancer diagnosis, this moment marks the beginning of a new era in treatment possibilities.